Clinical trials
Recurrent WHO Grade 4 Glioma clinical trials
Below are recruiting recurrent who grade 4 glioma clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07755397RecruitingPhase 1
Study of JBI-778 for lung, brain, and salivary gland tumors
This trial tests a new oral medication, JBI-778, in patients with certain types of lung cancer, brain tumors, or salivary gland cancer. The drug is designed to target specific genetic changes in these tumors, and the study aims to assess its safety and effectiveness.
Surat, GujaratAges 18 years+ - NCT04267978RecruitingPhase 2
Test drug combination for recurrent brain tumor growth
This Phase 2 study tests whether adding recombinant human endostatin to temozolomide and irinotecan can slow or control recurrent gliomas (brain tumors) after prior standard treatment. It may help by targeting tumor blood vessel growth while also using chemotherapy to attack cancer cells.
BeijingAges 18–70 - NCT07710690RecruitingPhase 1
Study of NRG-103 injection for recurrent high-grade glioma
This trial tests a new injection called NRG-103 for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard treatments. The goal is to see if it's safe and if it might help shrink the tumor.
ShanghaiAges 18 years+ - NCT07655869RecruitingEarly Phase 1
Lu177-DOTA-EB-RGD2 therapy for returning high-grade glioma
This trial tests a radioactive drug that targets a protein on tumor blood vessels to treat glioblastoma that has come back after standard treatment. It may help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07648823RecruitingEarly Phase 1
New radioactive treatment for recurrent brain tumors
This early-stage trial tests a new radioactive drug called [177Lu]Lu-XT771 injected directly into the brain cavity after glioblastoma surgery. It measures whether the drug is safe and helps slow tumor regrowth in patients whose cancer has come back after earlier treatments.
Beijing, Beijing MunicipalityAges 18–80 - NCT06160206RecruitingPhase 2
Study of retifanlimab, bevacizumab, and radiation for recurrent glioblastoma
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
Scottsdale, ArizonaAges 18 years+ - NCT06161610Recruiting
Laser treatment for returning high-grade glioma
This study tests a laser ablation treatment for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard therapy. The goal is to see if this minimally invasive laser procedure can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07551336RecruitingPhase 1
CAR-NK cells for recurrent glioblastoma and high-grade brain tumors
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
Shenzhen, GuangdongAges 18–75 - NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT07541781RecruitingPhase 1
Sitagliptin for recurrent grade 4 glioma
This trial tests whether the diabetes drug sitagliptin (Januvia) can help slow or shrink a recurrent grade 4 glioma (a type of brain tumor). It's for people whose tumor has come back after standard treatment and who have not used sitagliptin or Avastin before.
Iowa City, IowaAges 18 years+ - NCT07506239Recruiting
Laser therapy for low-grade brain tumors in young people
This trial tests a laser treatment called LITT for low-grade glioma (a type of brain tumor) that has come back or is growing despite prior treatment. It aims to see if the laser is safe and effective in young people aged 2 to 25.
San Francisco, CaliforniaAges 2–25 - NCT07480941RecruitingPhase 1
CAR-NK cell therapy for recurrent glioblastoma
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
Shenzhen, GuangdongAges 18–75 - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT06660056RecruitingPhase 1
GC001 injection for returning or growing high-grade brain tumors
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07306299RecruitingPhase 1
MRNA vaccine for recurrent high-grade glioma
This trial tests a new mRNA vaccine for people with a type of brain tumor called high-grade glioma that has come back or progressed. The vaccine is designed to help your immune system recognize and attack the tumor cells.
Hangzhou, ZhejiangAges 16 years+ - NCT07301268RecruitingPhase 2
GI-102 with or without pembrolizumab before brain surgery
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
Rochester, MinnesotaAges 18 years+ - NCT07268053RecruitingEarly Phase 1
B7-H3 drug for recurrent brain tumor or brain metastases
This trial tests a drug called GSK5764227 (a B7-H3 targeted antibody-drug conjugate) in people whose glioblastoma has come back after standard treatment, or who have brain metastases that need surgery. The goal is to see if the drug can help shrink or control the tumor.
Phoenix, ArizonaAges 18 years+ - NCT07110246RecruitingPhase 2
Dabrafenib and trametinib for BRAF-mutated low-grade gliomas
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
Birmingham, AlabamaAges 1–25 - NCT07061626RecruitingPhase 1
Radioactive drug for recurrent ependymoma and high-grade glioma
This trial tests a radioactive drug (Rhenium-186) injected directly into the brain tumor to see the highest safe dose for children and young adults with ependymoma or high-grade glioma that has come back or is not responding to standard treatments. It may help shrink the tumor without needing surgery right away.
Chicago, IllinoisAges 6–21 - NCT06964737RecruitingPhase 1
CAR T-cell therapy for recurrent brain tumors
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
Columbus, OhioAges 18 years+ - NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+ - NCT06860594RecruitingPhase 1
Triapine plus radiation for recurrent brain tumors
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
Duarte, CaliforniaAges 18 years+ - NCT06773481RecruitingPhase 1
BC008-1A injection for recurrent grade 4 glioma
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06838676RecruitingPhase 2
ACT001 for Newly or Previously Treated Brain Stem Glioma
This trial tests the drug ACT001 in people with a type of brain tumor called DIPG or other related high-grade gliomas. It aims to see if the drug can help control the tumor and improve outcomes.
Aurora, ColoradoAges 1–39
Hear when a new Recurrent WHO Grade 4 Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent who grade 4 glioma?
- Yes. Clin2 currently lists 87 recruiting recurrent who grade 4 glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent who grade 4 glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent who grade 4 glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.